CD274 and neoplasm: Due to the abundance and diversity of neoantigens generated in the absence of functional mismatch repair, immunotherapy using antagonists of the programmed death-1 (PD-1) receptor or its ligand PD-L1), with or without antagonists of the CTLA4 receptor, is an attractive option for patients with dMMR/MSI-H tumours.